Aptevo Therapeutics - נכסים נקיים למניה בודדת APVO

Aptevo Therapeutics (APVO) generates revenue through the supply of Alphanate for hemophilia and the development of cancer therapies. The company enhances efficiency via bio-screening and computational protein modeling, while management focuses on platform validation. The book value per share history on the GURU.Markets chart demonstrates capital accumulation, with the metric currently standing at 4.22, confirming the business's current volume of net assets.

Book value per share determines the portion of net equity attributable to a single common share after deducting all liabilities, allowing for an assessment of the business's intrinsic value. Analysis via the BVPS metric helps determine the extent to which Aptevo Therapeutics (APVO) assets cover its market capitalization during the development of its flagship bispecific antibody programs for targeted oncology therapy.